Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDC 1421

Drug Profile

PDC 1421

Alternative Names: ABV 1504; ABV 1505; BLI-1005; PDC-1421

Latest Information Update: 23 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical and Pharmaceutical Industry Technology and Development Center
  • Developer BioLite Inc
  • Class Antidepressants; Behavioural disorder therapies; Traditional Chinese medicine
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 07 Apr 2022 BioLite initiates a phase-II trial in Attention-deficit hyperactivity disorder in USA (PO) (NCT05202327)
  • 07 Apr 2022 Phase-II clinical trials in Attention-deficit hyperactivity disorder in Taiwan (PO) (NCT05202327)
  • 01 Nov 2021 American BriVision receives approval of Taiwan Central Institutional Review Board (CIRB) to initiate a phase II part 2 study in Attention-deficit hyperactivity disorder (ADHD) in Taiwan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top